Selected research
Industry Research
Urological Medications Industry Research Report 2026
Market perspective
The global Urological Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Urological Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Urological Medications market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Urological Medications market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Urological Medications include Abbott, Novartis, Merck, Lilly, Pfizer, GlaxoSmithKline, AbbVie, Viatris and Sanofi-aventis U.S. LLC, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Urological Medications market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Urological Medications.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Urological Medications Market by Company
Abbott
Novartis
Merck
Lilly
Pfizer
GlaxoSmithKline
AbbVie
Viatris
Sanofi-aventis U.S. LLC
Piramal Pharma Solutions
Mallinckrodt
Endo International
Bayer HealthCare Pharmaceuticals
Astellas Pharma
ADVANZ PHARMA
Urological Medications Segment by Type
Anticholinergics
Alpha Blockers
5-Alpha Inhibitors
Others
Urological Medications Segment by Application
OAB
ED
Prostate Cancer
BPH
SUI
Others
Urological Medications Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urological Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Urological Medications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anticholinergics
- Alpha Blockers
- 5-Alpha Inhibitors
- Others
Applications
- OAB
- ED
- Prostate Cancer
- BPH
- SUI
- Others
Companies covered
- Abbott
- Novartis
- Merck
- Lilly
- Pfizer
- GlaxoSmithKline
- AbbVie
- Viatris
- Sanofi-aventis U.S. LLC
- Piramal Pharma Solutions
- Mallinckrodt
- Endo International
- Bayer HealthCare Pharmaceuticals
- Astellas Pharma
- ADVANZ PHARMA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Urological Medications by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Anticholinergics
- 2.2.3 Alpha Blockers
- 2.2.4 5-Alpha Inhibitors
- 2.2.5 Others
- 2.3 Urological Medications by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 OAB
- 2.3.3 ED
- 2.3.4 Prostate Cancer
- 2.3.5 BPH
- 2.3.6 SUI
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Urological Medications Breakdown Data by Type
- 3.1 Global Urological Medications Historic Market Size by Type (2021-2026)
- 3.2 Global Urological Medications Forecasted Market Size by Type (2027-2032)
4 Urological Medications Breakdown Data by Application
- 4.1 Global Urological Medications Historic Market Size by Application (2021-2026)
- 4.2 Global Urological Medications Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Urological Medications Market Perspective (2021-2032)
- 5.2 Global Urological Medications Growth Trends by Region
- 5.2.1 Global Urological Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Urological Medications Historic Market Size by Region (2021-2026)
- 5.2.3 Urological Medications Forecasted Market Size by Region (2027-2032)
- 5.3 Urological Medications Market Dynamics
- 5.3.1 Urological Medications Industry Trends
- 5.3.2 Urological Medications Market Drivers
- 5.3.3 Urological Medications Market Challenges
- 5.3.4 Urological Medications Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Urological Medications Players by Revenue
- 6.1.1 Global Top Urological Medications Players by Revenue (2021-2026)
- 6.1.2 Global Urological Medications Revenue Market Share by Players (2021-2026)
- 6.2 Global Urological Medications Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Urological Medications Head Office and Area Served
- 6.4 Global Urological Medications Players, Product Type & Application
- 6.5 Global Urological Medications Manufacturers Established Date
- 6.6 Global Urological Medications Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Urological Medications Market Size (2021-2032)
- 7.2 North America Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Urological Medications Market Size by Country (2021-2026)
- 7.4 North America Urological Medications Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Urological Medications Market Size (2021-2032)
- 8.2 Europe Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Urological Medications Market Size by Country (2021-2026)
- 8.4 Europe Urological Medications Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Urological Medications Market Size (2021-2032)
- 9.2 Asia-Pacific Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Urological Medications Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Urological Medications Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Urological Medications Market Size (2021-2032)
- 10.2 South America Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Urological Medications Market Size by Country (2021-2026)
- 10.4 South America Urological Medications Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Urological Medications Market Size (2021-2032)
- 11.2 Middle East & Africa Urological Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Urological Medications Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Urological Medications Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott
- 12.1.1 Abbott Company Information
- 12.1.2 Abbott Business Overview
- 12.1.3 Abbott Revenue in Urological Medications Business (2021-2026)
- 12.1.4 Abbott Urological Medications Product Portfolio
- 12.1.5 Abbott Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Urological Medications Business (2021-2026)
- 12.2.4 Novartis Urological Medications Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Urological Medications Business (2021-2026)
- 12.3.4 Merck Urological Medications Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Lilly
- 12.4.1 Lilly Company Information
- 12.4.2 Lilly Business Overview
- 12.4.3 Lilly Revenue in Urological Medications Business (2021-2026)
- 12.4.4 Lilly Urological Medications Product Portfolio
- 12.4.5 Lilly Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Urological Medications Business (2021-2026)
- 12.5.4 Pfizer Urological Medications Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 GlaxoSmithKline
- 12.6.1 GlaxoSmithKline Company Information
- 12.6.2 GlaxoSmithKline Business Overview
- 12.6.3 GlaxoSmithKline Revenue in Urological Medications Business (2021-2026)
- 12.6.4 GlaxoSmithKline Urological Medications Product Portfolio
- 12.6.5 GlaxoSmithKline Recent Developments
- 12.7 AbbVie
- 12.7.1 AbbVie Company Information
- 12.7.2 AbbVie Business Overview
- 12.7.3 AbbVie Revenue in Urological Medications Business (2021-2026)
- 12.7.4 AbbVie Urological Medications Product Portfolio
- 12.7.5 AbbVie Recent Developments
- 12.8 Viatris
- 12.8.1 Viatris Company Information
- 12.8.2 Viatris Business Overview
- 12.8.3 Viatris Revenue in Urological Medications Business (2021-2026)
- 12.8.4 Viatris Urological Medications Product Portfolio
- 12.8.5 Viatris Recent Developments
- 12.9 Sanofi-aventis U.S. LLC
- 12.9.1 Sanofi-aventis U.S. LLC Company Information
- 12.9.2 Sanofi-aventis U.S. LLC Business Overview
- 12.9.3 Sanofi-aventis U.S. LLC Revenue in Urological Medications Business (2021-2026)
- 12.9.4 Sanofi-aventis U.S. LLC Urological Medications Product Portfolio
- 12.9.5 Sanofi-aventis U.S. LLC Recent Developments
- 12.10 Piramal Pharma Solutions
- 12.10.1 Piramal Pharma Solutions Company Information
- 12.10.2 Piramal Pharma Solutions Business Overview
- 12.10.3 Piramal Pharma Solutions Revenue in Urological Medications Business (2021-2026)
- 12.10.4 Piramal Pharma Solutions Urological Medications Product Portfolio
- 12.10.5 Piramal Pharma Solutions Recent Developments
- 12.11 Mallinckrodt
- 12.11.1 Mallinckrodt Company Information
- 12.11.2 Mallinckrodt Business Overview
- 12.11.3 Mallinckrodt Revenue in Urological Medications Business (2021-2026)
- 12.11.4 Mallinckrodt Urological Medications Product Portfolio
- 12.11.5 Mallinckrodt Recent Developments
- 12.12 Endo International
- 12.12.1 Endo International Company Information
- 12.12.2 Endo International Business Overview
- 12.12.3 Endo International Revenue in Urological Medications Business (2021-2026)
- 12.12.4 Endo International Urological Medications Product Portfolio
- 12.12.5 Endo International Recent Developments
- 12.13 Bayer HealthCare Pharmaceuticals
- 12.13.1 Bayer HealthCare Pharmaceuticals Company Information
- 12.13.2 Bayer HealthCare Pharmaceuticals Business Overview
- 12.13.3 Bayer HealthCare Pharmaceuticals Revenue in Urological Medications Business (2021-2026)
- 12.13.4 Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio
- 12.13.5 Bayer HealthCare Pharmaceuticals Recent Developments
- 12.14 Astellas Pharma
- 12.14.1 Astellas Pharma Company Information
- 12.14.2 Astellas Pharma Business Overview
- 12.14.3 Astellas Pharma Revenue in Urological Medications Business (2021-2026)
- 12.14.4 Astellas Pharma Urological Medications Product Portfolio
- 12.14.5 Astellas Pharma Recent Developments
- 12.15 ADVANZ PHARMA
- 12.15.1 ADVANZ PHARMA Company Information
- 12.15.2 ADVANZ PHARMA Business Overview
- 12.15.3 ADVANZ PHARMA Revenue in Urological Medications Business (2021-2026)
- 12.15.4 ADVANZ PHARMA Urological Medications Product Portfolio
- 12.15.5 ADVANZ PHARMA Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst